Abstract
Background and Aim: The global pandemic of COVID-19 has posed an enormous threat to the economy and people's lives across various countries. Patients with COVID-19 most commonly present with respiratory symptoms. However, gastrointestinal (GI) symptoms can also occur. We aimed to study the relationship between GI symptoms and disease prognosis in patients with COVID-19.
Methods: In a single-center and retrospective cohort study, the outcomes in COVID-19 patients with or without GI symptoms were compared. The propensity score is a conditional probability of having a particular exposure (COVID-19 patients with GI symptoms vs. without GI symptoms) given a set of baseline measured covariates. Survival was estimated using the Kaplan-Meier method, and any differences in survival were evaluated with a stratified log-rank-test. To explore the GI symptoms associated with ARDS, non-invasive ventilator treatment, tracheal intubation, tracheotomy, and CRRT, univariable and multivariable COX regression models were used.
Results: Among 1,113 eligible patients, 359 patients with GI symptoms and 718 without GI symptoms had similar propensity scores and were included in the analyses. Patients with GI symptoms, as compared with those without GI symptoms, were associated with a similar risk of death, but with higher risks of ARDS, non-invasive mechanical ventilation in COVID-19 patients, respectively.
Conclusions: The presence of GI symptoms was associated with a high risk of ARDS, non-invasive mechanical ventilation and tracheal intubation in patients with COVID-19 but not mortality.
Keywords: gastrointestinal symptoms, COVID-19, prognosis, SARS-CoV-2 (COVID-19), ARDS (acute respiratory distress syndrome)
Introduction
The global pandemic of COVID-19 has posed an enormous threat to the economy and people's lives across various countries (1, 2). The clinical spectrum of COVID-19 appears to be wide, ranging from asymptomatic infection, mild to critically-ill cases (3–6). Significant comorbidities such as type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVDs) were associated with developing severe and critical COVID-19 condition (7, 8). In severe cases, patients can rapidly develop acute respiratory distress syndrome (ARDS), septic shock, and multiple organ dysfunction syndromes (9). The most common symptoms of COVID-19 are fever, cough, fatigue, myalgia, and dyspnoea (10). Gastrointestinal (GI) symptoms were also observed in a significant proportion of patients (11–13), which were possibly due to the enrichment and infection of SARS-CoV-2 in the gastrointestinal tract.
Recent studies showed that angiotensin converting enzyme 2 (ACE2) plays a crucial role in the cellular infection with SARS-CoV-2 virus (14–16). Although ACE2 was found to be widely expressed across tissues, it was considered to be intestine-specific, and was enriched more than 4-fold in the epithelia of the intestinal tract compared with other tissues (17). SARS-CoV-2 disrupts ACE2 activity and infects the intestinal epithelium by inducing cytotoxicity (18), and then it is shed into feces, resulting in GI symptoms and/or positive SARS-CoV-2 viral load or RNA in stool (19). It is known that gastrointestinal problems in critically-ill patients were common and were associated with unfavorable outcomes (20). Trillions of diverse bacteria located in the intestinal tract and constituted the intestinal “microbiota” (21). Our previous studies found that bacteria and toxins enter into blood after intestinal mucosa injury caused by adverse stimulates, leading to damage of multiple remote organs (22). The impact of intestinal mucosa injured by SARS-CoV-2 infection and consequence on prognosis in patients with COVID-19 remains unknown. In this study, we investigated patients with GI symptoms, who were admitted to Renmin hospital of Wuhan University, Wuhan, China, associated with prognosis or outcome in patients with COVID-19.
Materials and Methods
Study Design and Participants
This single-center, retrospective cohort study included two cohorts of inpatients from East Campus of Renmin Hospital of Wuhan University. It was approved by the Institutional Review Board at Renmin hospital of Wuhan University (No. WDRY2020-K111, March 12, 2020) and have been performed in accordance with the ethical standards laid down in an appropriate version of the Declaration of Helsinki (as revised in Brazil 2013). Due to the urgency of this infectious disease, data analysis was performed anonymously and written informed consent was exempted. The East Campus of Renmin Hospital of Wuhan University is one of the major hospitals designated by the government to be responsible for patients with COVID-19 who are critically-ill, pregnant, or require surgery from January 25, 2020. This study included a total of 1,117 hospitalized patients with COVID-19 from January 25, 2020 to March 31, 2020. The diagnosis of COVID-19 according to the diagnostic criteria established by WHO and the New Coronavirus Pneumonia Prevention and Control Program (5th−7th edition) (23–25) issued by the National Health Commission of China. COVID-19 patients were diagnosed with clinical symptoms together with nasopharyngeal swabs tested positive for SARS-CoV-2 using real-time reverse transcription PCR (RT-PCR). All patients received chest radiography or chest CT scan on admission. Patients were divided into groups with gastrointestinal (GI) symptom or without GI symptom according to the presence or absence of GI symptoms.
Data Collection
All information including epidemiological, demographic, clinical, laboratory, treatment, and outcome data were extracted from the medical record system of the Renmin Hospital of Wuhan University, and were collected and reviewed by three investigators using a standardized data collection form. All data were collected including age, sex, exposure history, comorbidities (hypertension, diabetes, coronary heart disease, cerebrovascular disease, chronic heart failure, liver dysfunction, chronic kidney disease, and chronic pulmonary disease), GI symptoms (abdominal pain, acid reflux, nausea or vomiting, abdominal distension, diarrhea, tenesmus, and belching), common symptoms (fever, cough, chest tightness, chest pain, dyspnoea, myalgia, headache, and fatigue), laboratory values, and radiologic findings on admission, treatment [proton pump inhibitors (PPIs), antivirals, antibiotics, corticosteroids, and high-flow nasal oxygen therapy], as well as complications [ARDS, acute kidney injury (AKI), and acute liver injury] and mortality status. All data were double checked independently and further verifications were done wherever necessary.
Definition
The definition of patients with GI symptoms is that the patients had at least one of the GI symptoms of abdominal pain, acid reflux, nausea or vomiting, abdominal distension, diarrhea, tenesmus, and belching. Fever was defined as having an axillary temperature of >37.3°C. Lymphocytopenia was defined as lymphocyte count <0.8 × 109/L (26). The patients with COVID-19 were divided into four grades according to the degree of disease severity, based on the Chinese management guideline for COVID-19 (5th−7th edition) (23–25): Mild (slight clinical symptoms without CT imaging features of pneumonia); Moderate (fever and/or respiratory symptoms plus imaging features of COVID-19 pneumonia); Severe [respiratory distress (respiratory rate ≥30 breaths/min) together with the oxygen saturation ≤93% or arterial oxygen pressure (PaO2)/fractional inspired oxygen (FiO2) ratio ≤300 mmHg]; Critical [respiratory failure requiring mechanical ventilation or multiorgan failure requiring intensive care unit (ICU) admission]. Acute respiratory distress syndrome was diagnosed according to the Berlin definition (27). Acute kidney injury was identified on the basis of serum creatinine level according to the KDIGO clinical practice guideline (28). The definition of liver damage was alanine aminotransferase (ALT) >50 U/L or aspartate aminotransferase (AST) >40 U/L (29).
Outcomes
The correlation of the GI symptoms of COVID-19 associated with mortality and other clinical features and interventions including ARDS, non-invasive ventilator treatment, tracheal intubation, tracheotomy, and continuous renal replacement therapy (CRRT) were analyzed. Other outcomes including the rate of SARS-CoV-2-related AKI, acute liver injury and the proportion of patients requiring high-flow nasal oxygen therapy, non-invasive mechanical ventilation, tracheal intubation, tracheotomy, CRRT, and ICU admission were also analyzed.
Statistical Analyses
Given the differences in the baseline characteristics between eligible participants in the two groups, propensity-score matching was used to authenticate a cohort of patients with similar baseline characteristics. The propensity score is a conditional probability of having a particular exposure (COVID-19 patients with GI symptoms vs. without GI symptoms) given a set of baseline measured covariates. The propensity score was estimated, with COVID-19 patients with GI symptoms as the dependent variable, and age, sex, exposure history, comorbidities as covariates. Matching was performed with the use of a 1:2 matching protocol without replacement (greedy-matching algorithm), with a caliper width equal to 0.2 of the standard deviation of the logit of the propensity score. Standardized differences and p-values were estimated for all the baseline covariates before and after matching to assess pre-match imbalance and post-match balance. Standardized differences of <10.0% for a given covariate indicate a relatively small imbalance.
Continuous and categorical variables were presented as median (IQR) and n (%), respectively. We used the Mann-Whitney U-test, χ2-test, or Fisher's exact-test to compare differences between patients with and without GI symptoms where appropriate. Survival was estimated using the Kaplan-Meier method, and any differences in survival were evaluated with a stratified log-rank-test. To explore the GI symptoms associated with ARDS, non-invasive ventilator treatment, tracheal intubation, tracheotomy, and CRRT, univariable and multivariable COX regression models were used. A two-sided α of <0.05 was considered statistically significant. Data were analyzed with the use of the statistical packages R (The R Foundation; http://www.r-project.org; version 3.4.3 2018–02-18) and EmpowerStats (www.empowerstats.com; X&Y Solutions Inc.).
Results
Demographic and Epidemiological Characteristics
A total of 1,206 adult patients of COVID-19 were enrolled in our study from 25 January, 2020 to 31 March, 2020 in East Campus of Renmin hospital of Wuhan university; Of those, 93 were considered to be ineligible, including 66 patients with chronic gastrointestinal disease, 20 patients who were pregnant and 7 patients missing key information in their medical records. Final 1,077 patients were included in our study (Figure 1). There were differences between the two groups in several of the baseline variables before propensity score matching (PSM). After excluded 36 patients with PSM, 359 patients with GI symptoms were matched against 718 patients without GI symptoms. Their demographic data and other characteristics including comorbidities are presented in the Table 1.
Figure 1.
Enrollment flowchart. GI, gastrointestinal injury.
Table 1.
Baseline characteristics of patients with COVID-19 before and after propensity score matching.
| Characteristic | Before matching | After matching | ||||||
|---|---|---|---|---|---|---|---|---|
| All patients (n = 1,113) | Patients with GI symptoms (n = 369) | Patients without GI symptoms (n = 744) | p-value | All patients (n = 1,077) | Patients with GI symptoms (n = 359) | Patients without GI symptoms (n = 718) | p-value | |
| Age, year | ||||||||
| Median (IQR) | 59.0 (47.0–68.0) |
61.0 (50.0–70.0) |
57.5 (46.0–67.0) |
<0.001 | 59.0 (47.0–68.0) |
60.0 (48.0–70.0) |
59.0 (47.0–67.0) |
0.065 |
| Distribution, n (%) | ||||||||
| <15 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| 15–44 | 238 (21.4) | 65 (17.6) | 173 (23.3) | 219 (20.0) | 65 (18.1) | 154 (21.5) | ||
| 45–64 | 476 (42.8) | 152 (41.2) | 324 (43.5) | 476 (42.7) | 152 (42.3) | 324 (45.1) | ||
| ≥65 | 399 (35.8) | 152 (41.2) | 247 (33.2) | 382 (34.3) | 142 (39.6) | 240 (33.4) | ||
| Sex, n (%) | 0.496 | 0.763 | ||||||
| Male | 550 (49.4) | 177 (48.0) | 373 (50.1) | 532 (49.4) | 175 (48.7) | 357 (49.7) | ||
| Female | 563 (50.6) | 192 (52.0) | 371 (49.9) | 545 (50.6) | 184 (51.3) | 361 (50.3) | ||
| Exposure history, n (%) | 153 (13.7) | 49 (13.3) | 104 (14.0) | 0.750 | 152 (14.1) | 48 (13.4) | 104 (14.5) | 0.621 |
| Comorbidity, n (%) | 574 (51.6) | 203 (55.0) | 371 (49.9) | 0.106 | 557 (51.7) | 193 (53.8) | 364 (50.7) | 0.343 |
| Hypertension | 368 (33.1) | 133 (36.0) | 235 (31.6) | 0.137 | 355 (33.0) | 124 (34.5) | 231 (32.2) | 0.436 |
| Diabetes | 150 (13.5) | 59 (16.0) | 91 (12.2) | 0.084 | 145 (13.5) | 55 (15.3) | 90 (12.5) | 0.207 |
| CHD | 91 (8.2) | 32 (8.7) | 59 (7.9) | 0.671 | 86 (8.0) | 29 (8.1) | 57 (7.9) | 0.937 |
| Cerebrovascular disease | 31 (2.8) | 12 (3.3) | 19 (2.6) | 0.505 | 27 (2.5) | 10 (2.8) | 17 (2.4) | 0.683 |
| Chronic heart failure | 35 (3.1) | 18 (4.9) | 17 (2.3) | 0.020 | 32 (3.0) | 16 (4.5) | 16 (2.2) | 0.042 |
| Liver dysfunction | 89 (8.0) | 29 (7.9) | 60 (8.1) | 0.905 | 87 (8.1) | 28 (7.8) | 59 (8.2) | 0.812 |
| CKD | 57 (5.1) | 29 (7.9) | 28 (3.8) | 0.004 | 52 (4.8) | 25 (7.0) | 27 (3.8) | 0.056 |
| Chronic pulmonary disease | 59 (5.3) | 27 (7.3) | 32 (4.3) | 0.035 | 58 (5.4) | 26 (7.2) | 32 (4.5) | 0.174 |
Data are shown as median (IQR) or n (%). p-values were calculated using Mann-Whitney U-test, χ2-test, or Fisher's exact-test, as appropriate. GI, gastrointestinal; CHD, Coronary heart disease; CKD, Chronic kidney disease.
Clinical, Laboratory, and Radiographic Characteristics
Diarrhea (208, 57.9%), nausea or vomiting (71, 19.8%), abdominal pain (38, 10.6%) and abdominal distension (38, 10.6%) were the most frequently observed GI manifestations (Table 2). For those 359 patients with GI symptoms, 107 (29.8%) were present on initial presentation and 252 (70.2%) were present during hospitalization. Fever, cough, fatigue, chest tightness, and dyspnoea were the most common symptoms amongst all COVID-19 patients; Patients with GI symptoms had fever (287, 79.9%; p < 0.001), cough (168, 46.8%; <0.001), fatigue (103, 28.7%; <0.001), chest tightness (60, 16.7%; 0.019), and dyspnoea (52, 14.5%; <0.001), which were significantly higher than those in patients without GI symptoms (Table 2). Lymphocyte count in COVID-19 patients with GI symptoms was significantly lower than that in patients without GI symptoms [1.0 (0.7–1.4) vs. 1.3 (0.9–1.7), p < 0.001]; Lymphocytopenia occurred in 122 (34%) patients with GI symptoms. AST [27.0 (20.0–40.0) vs. 24.0 (18.0–38.0), p = 0.008], LDH [258.0 (200.0–355.0) vs. 227.0 (181.0–309.0)], CRP [30.8 (9.4–68.9) vs. 9.4 (2.4–54.1), p < 0.001] and procalcitonin [0.06 (0.04–0.14) vs. 0.05 (0.03–0.09), p < 0.001] were substantially higher in the COVID-19 patients with GI symptoms. Moreover, although most radiographic findings were similar between COVID-19 patients with and without GI symptoms, the rate of bilateral lung pneumonia in COVID-19 patients with GI symptoms was much higher than that in patients without GI symptoms [301 (83.8%) vs. 542 (75.5%), p = 0.002]. All these comparisons in the two groups are presented in the Table 3.
Table 2.
Clinical features, disease classification of patients with COVID-19 with and without GI symptoms.
| All patient (n = 1077) | Patients with GI symptoms (n = 359) | Patients without GI symptoms (n = 718) | p-value | |
|---|---|---|---|---|
| GI symptoms | ||||
| Abdominal pain | 38 (3.5) | 38 (10.6) | 0 (0) | |
| Acid reflux | 12 (1.1) | 12 (3.3) | 0 (0) | |
| Nausea or vomiting | 71 (6.6) | 71 (19.8) | 0 (0) | |
| Abdominal distension | 38 (3.5) | 38 (10.6) | 0 (0) | |
| Diarrhea | 208 (19.3) | 208 (57.9) | 0 (0) | |
| Tenesmus | 9 (0.8) | 9 (2.5) | 0 (0) | |
| Belching | 6 (0.6) | 6 (1.7) | 0 (0) | |
| Other symptoms | ||||
| Fever | 777 (72.1) | 287 (79.9) | 490 (68.2) | <0.001 |
| Cough | 267 (24.8) | 168 (46.8) | 99 (13.8) | <0.001 |
| Chest tightness | 143 (13.3) | 60 (16.7) | 83 (11.6) | 0.019 |
| Chest pain | 20 (1.9) | 6 (1.7) | 14 (1.9) | 0.816 |
| Dyspnoea | 105 (9.7) | 52 (14.5) | 53 (7.4) | <0.001 |
| Myalgia | 61 (5.7) | 31 (8.6) | 30 (4.2) | 0.003 |
| Headache | 28 (2.6) | 12 (3.3) | 16 (2.2) | 0.311 |
| Fatigue | 240 (22.3) | 103 (28.7) | 137 (19.1) | <0.001 |
| Time of onset of GI symptoms | ||||
| On initial presentation | 107 (9.9) | 107 (29.8) | 0 (0) | |
| During hospitalization | 252 (23.4) | 252 (70.2) | 0 (0) | |
| Disease classification | <0.001* | |||
| Mild | 29 (2.7) | 2 (0.5) | 27 (3.8) | |
| Moderate | 485 (45.0) | 118 (32.9) | 367 (51.1) | |
| Severe | 502 (46.6) | 212 (59.1) | 290 (40.4) | |
| Critical | 61 (5.7) | 27 (7.5) | 34 (4.7) |
Data are median (IQR) or n (%). p-values were calculated using Mann-Whitney U-test, χ2-test, or Fisher's exact-test, as appropriate. GI, gastrointestinal.
χ2-test comparing all subcategories.
Table 3.
Laboratory and radiographic findings of patients with COVID-19 with and without GI symptoms.
| All patients (n = 1,077) | Patients with GI symptoms (n = 359) | Patients without GI symptoms (n = 718) | p-value | |
|---|---|---|---|---|
| Laboratory findings | ||||
| White blood cell count, × 109/L | 5.6 (4.4–7.3) | 5.5 (4.2–7.3) | 5.7 (4.5–7.3) | 0.091 |
| Neutrophil count, × 109/L | 3.6 (2.5–5.3) | 3.7 (2.5–5.6) | 3.6 (2.6–5.3) | 0.910 |
| Lymphocyte count, × 109/L | 1.1 (0.8–1.6) | 1.0 (0.7–1.4) | 1.3 (0.9–1.7) | <0.001 |
| Hemoglobin, g/L | 125.0 (114.0–135.0) | 125.0 (114.0–133.0) | 125.0 (115.0–135.0) | 0.531 |
| Anemia | 381 (35.4) | 132 (36.8) | 249 (34.7) | 0.499 |
| Platelet count, × 109/L | 214 (168.0–273.0) | 207 (158.0–270.5) | 219.0 (174.0–277.0) | 0.006 |
| Albumin, g/L | 38.0 (34.4–41.1) | 36.8 (33.7–40.0) | 38.5 (34.7–41.4) | <0.001 |
| ALT, U/L | 25.0 (17.0–42.0) | 26.0 (17.0–41.0) | 24.0 (16.0–42.0) | 0.607 |
| AST, U/L | 25.0 (19.0–38.0) | 27.0 (20.0–40.0) | 24.0 (18.0–38.0) | 0.008 |
| Urea, mmol/L | 4.7 (3.7–6.2) | 4.8 (3.7–6.5) | 4.7 (3.7–6.1) | 0.332 |
| Creatinine, μmol/L | 59.0 (49.0–71.0) | 59.0 (49.0–73.0) | 59.0 (50.0–70.0) | 0.639 |
| LDH, U/L | 237.0 (188.0–325.0) | 258.0 (200.0–355.0) | 227.0 (181.0–309.0) | <0.001 |
| PT, s | 11.9 (11.2–12.6) | 12.0 (11.3–12.7) | 11.8 (11.2–12.5) | 0.008 |
| APTT, s | 27.5 (25.6–29.9) | 27.8 (25.7–30.8) | 27.3 (29.4–25.5) | 0.009 |
| CRP, mg/L | 16.8 (3.0–60.5) | 30.8 (9.4–68.9) | 9.4 (2.4–54.1) | <0.001 |
| D-dimer, μg/mL | 0.7 (0.4–1.9) | 0.9 (0.4–2.5) | 0.6 (0.3–1.6) | <0.001 |
| Procalcitonin, ng/mL | 0.05 (0.03–0.10) | 0.06 (0.04–0.14) | 0.05 (0.03–0.09) | <0.001 |
| Glu, mmol/L | 5.5 (4.8–6.9) | 5.6 (4.9–7.1) | 5.3 (4.8–6.7) | 0.007 |
| Na, mmol/L | 141.0 (139.0–145.0) | 141.0 (138.0–144.0) | 142.0 (139.0–145.0) | 0.009 |
| K, mmol/L | 4.0 (3.7–4.3) | 4.0 (3.6–4.4) | 4.0 (3.7–4.3) | 0.376 |
| Ca, mmol/L | 2.1 (2.0–2.2) | 2.1 (2.0–2.2) | 2.2 (2.1–2.3) | <0.001 |
| Radiologic findings | ||||
| Bilateral | 843 (78.3) | 301 (83.8) | 542 (75.5) | 0.002 |
| Ground-glass opacity | 656 (60.9) | 225 (62.7) | 431 (60.0) | 0.401 |
| Patchy shadows | 612 (56.8) | 165 (46.0) | 447 (62.3) | <0.001 |
| Diffuse interstitial infiltrations | 14 (1.3) | 8 (2.2) | 6 (0.8) | 0.083 |
Data are median (IQR) or n (%). p-values were calculated using Mann-Whitney U-test, χ2-test, or Fisher's exact-test, as appropriate. GI, gastrointestinal; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactic dehydrogenase; PT, prothrombin time; APTT, activated partial thromboplastin time; CRP, C-reactive protein.
Treatment, Complications, and Clinical Outcomes
The number of patients receiving antivirals [342 (95.3%) vs. 648 (90.3%), p = 0.004], antibiotics [286 (79.7%) vs. 479 (66.7%), p < 0.001], and corticosteroids [148 (41.2) vs. 244 (34.0), p = 0.020] were significantly different between the COVID-19 patients with and without GI symptoms (Table 4). 298 (83.0%) COVID-19 patients with GI symptoms were treated with high-flow nasal oxygen therapy, 54 (15%) with non-invasive mechanical ventilation, 20 (5.6%) with tracheal intubation ventilation, 7 (1.9%) with CRRT, which were higher than those in patients without GI symptoms, respectively (Table 4). Acute respiratory distress syndrome was the most frequently observed complication, in addition to AKI and acute liver injury. The rate of ARDS in patients with GI symptoms was higher than that in patients without GI symptoms [72 (20.1%) vs. 61 (8.5), p < 0.001]. As of March 31, 785 (72.9%) patients with COVID-19 have been discharged from hospital, and 207 (19.2%) patients remained in hospital.
Table 4.
Treatment, complications and clinical outcomes of patients with COVID-19 with or without GI symptoms.
| All patients (n = 1,077) | Patients with GI symptoms (n = 359) | Patients without GI symptoms (n = 718) | p-value | |
|---|---|---|---|---|
| Treatments | ||||
| PPIs | 460 (42.7) | 205 (57.1) | 255 (35.5) | <0.001 |
| Antivirals | 990 (91.9) | 342 (95.3) | 648 (90.3) | 0.004 |
| Antibiotics | 765 (71.0) | 286 (79.7) | 479 (66.7) | <0.001 |
| Corticosteroids | 392 (36.4) | 148 (41.2) | 244 (34.0) | 0.020 |
| High-flow nasal oxygen therapy | 849 (78.8) | 298 (83.0) | 551 (76.7) | 0.018 |
| Non-invasive mechanical ventilation | 99 (9.2) | 54 (15.0) | 45 (6.3) | <0.001 |
| Tracheal intubation | 33 (3.1) | 20 (5.6) | 13 (1.8) | <0.001 |
| Tracheotomy | 8 (0.7) | 4 (1.1) | 4 (0.6) | 0.452 |
| CRRT | 9 (0.8) | 7 (1.9) | 2 (0.3) | 0.008 |
| ICU admission | 52 (4.8) | 22 (6.1) | 30 (4.2) | 0.159 |
| ICU length of stay, days | 14.0 (8.0–24.0) | 15.5 (8.0–24.8) | 14.0 (8.2–17.2) | 0.498 |
| Complications | ||||
| ARDS | 133 (12.3) | 72 (20.1) | 61 (8.5) | <0.001 |
| AKI | 13 (1.5) | 5 (1.4) | 8 (1.1) | 0.693 |
| Acute liver injury | 16 (1.5) | 6 (1.7) | 10 (1.4) | 0.791 |
| Hospital length of stay, days | 16.0 (9.0–32.0) | 24.8 (12.0–36.0) | 14.0 (8.0–28.0) | <0.001 |
| Clinical outcomes | ||||
| Discharge from hospital | 785 (72.9) | 254 (70.8) | 531 (74.0) | 0.265 |
| Death | 85 (7.9) | 34 (9.5) | 51 (7.1) | 0.174 |
| Staying in hospital | 207 (19.2) | 71 (19.7) | 136 (19.9) |
Data are median (IQR) or n (%). p-values were calculated using Mann-Whitney U-test, χ2-test, or Fisher's exact-test, as appropriate. GI, gastrointestinal; PPIs, proton pump inhibitors; CRRT, continuous renal replacement therapy; ARDS, acute respiratory distress syndrome; AKI, acute kidney injury; ICU, intensive care unit.
Correlation of Measures
Kaplan-Meier curves showed that there was no significant difference (p = 0.479) in mortality between COVID-19 patients with and without GI symptoms (Figure 2). The univariate regression analysis (Table 5) showed that the patients with GI symptoms was significantly associated with developing ARDS (HR 2.7, 95%CI 1.9–3.9, p < 0.001), requiring non-invasive mechanical ventilation (HR 2.6, 95%CI 1.7–4.0, p < 0.001), tracheal intubation (HR 3.2, 95%CI 1.6–6.5, p < 0.001), and CRRT (HR 7.1, 95%CI 1.5–34.4, P = 0.015). In the multivariate analysis, after the adjusting with lymphocyte, PLT, Albumin, Urea, Creatinine, LDH, PT, APTT, D-dimer, CRP, and Procalcitonin, patients with GI symptoms independently associated with non-invasive mechanical ventilation (HR 3.1, 95%CI 1.8–5.4, p < 0.001), tracheal intubation (HR 2.4, 95%CI 1.1–5.5, p = 0.037) and ARDS (HR 2.8, 95%CI 1.7–4.6, p < 0.001). There was no association between patients with GI symptoms and the requirement for CRRT (HR 5.1, 95%CI 0.5–53.0, P = 0.175). After adjusted with variables in Adjust I model and antiviral treatment, antibiotics and corticosteroids, the presence of GI symptoms remained an independent predictor for ARDS (HR 2.9, 95%CI 1.8–5.0, p < 0.001), non-invasive mechanical ventilation (HR 3.3, 95%CI 1.9–5.7, p < 0.001), and tracheal intubation (HR 2.5, 95%CI 1.1–6.0, p = 0.035) in COVID-19 patients.
Figure 2.
Kaplan-Meier (KM) survival curve for COVID-19 patients with or without GI (gastrointestinal) symptoms. p-values were for differences by log-rank-test.
Table 5.
Univariate and multivariate analysis for non-invasive mechanical ventilation, tracheal intubation, CRRT, and ARDS in COVID-19 patients with GI symptoms.
| Hazare ratio | 95%CI | p-value | |
|---|---|---|---|
| ARDS | |||
| Unadjusted | 2.7 | 1.9–3.9 | <0.001 |
| Adjusted I | 2.8 | 1.7–4.6 | <0.001 |
| Adjusted II | 2.9 | 1.8–5.0 | <0.001 |
| Non-invasive mechanical ventilation | |||
| Unadjusted | 2.6 | 1.7–4.0 | <0.001 |
| Adjusted I | 3.1 | 1.8–5.4 | <0.001 |
| Adjusted II | 3.3 | 1.9–5.7 | <0.001 |
| Tracheal intubation | |||
| Unadjusted | 3.2 | 1.6–6.5 | 0.001 |
| Adjusted I | 2.4 | 1.1–5.5 | 0.037 |
| Adjusted II | 2.5 | 1.1–6.0 | 0.035 |
| CRRT | |||
| Unadjusted | 7.1 | 1.5–34.4 | 0.015 |
| Adjusted I | 5.1 | 0.5–53.0 | 0.175 |
| Adjusted II | 6.1 | 0.5–71.3 | 0.149 |
Adjust I model adjusting for Lymphocyte, PLT, Albumin, Urea, Creatinine, LDH, PT, APTT, D-dimer, CRP, and Procalcitonin; Adjust II model adjusting by variables in Adjust I model plus antiviral treatment, antibiotics, and corticosteroids. CRRT, continuous renal replacement therapy; ARDS, acute respiratory distress syndrome.
Discussion
This retrospective cohort study of patients with COVID-19 showed that gastrointestinal (GI) symptoms were associated with a higher risk of ARDS, non-invasive mechanical ventilation, and tracheal intubation. The risk of death was similar amongst COVID-19 patients with or without GI symptoms. Many studies have confirmed that GI symptoms in COVID-19 patients are associated with the disease prognosis. Hajifathalian et al. (30) reported a lower mortality rate in patients with GI symptoms compared to those without any GI symptoms. Another study from Spain involving 2,226 patients with COVID-19 came to similar conclusions (31). In contrast, many studies have shown that GI symptoms are associated with poor prognosis. A meta-analysis reported that patients with GI symptoms had a higher rate of severe or critical COVID-19 infection compared to patients without any GI symptoms (32). To our knowledge, this is the first study examining the relationship between GI symptoms and prognosis in patients with COVID-19 with a relatively large sample size. In previously published studies of COVID-19 patients with GI symptoms, the patient numbers were too small to conclude the characteristics and mortality of these patients with SARS-CoV-2 pneumonia (29, 33, 34).
Although COVID-19 is characterized by respiratory tract manifestations, GI symptoms are not uncommon. In some cases, GI symptoms, particularly diarrhea, can be the initial presentation of COVID-19 in patients who may later (or never) present with respiratory symptoms (35). Moreover, another research from Wuhan showed that patients with GI symptoms risked not being promptly recognized, leading to a delayed diagnosis of COVID-19 (12). These patients were diagnosed as COVID-19 positive with SARS-CoV-2 nucleic acid in stool or rectal swabs (36). Among the total of 1,113 COVID-19 patients enrolled, the rate of patients with GI symptoms was 33.2%, which was higher than the data reported previously (3, 29). The reason of this discrepancy is unknown but may be related to the main task of East Campus of Renmin Hospital of Wuhan University in undertaking the treatment of critical COVID-19 patients.
In our study, the clinical characteristics of COVID-19 patients with GI symptoms were a significantly higher rate of fever, cough, chest tightness, dyspnoea, myalgia and fatigue, and had increased complication of ARDS and a higher tendency toward higher disease severity (rate of severe/critical type and mechanical ventilation) compared with COVID-19 patients without GI symptoms, which is consistent with a study reported previously (29). This may be related to bacterial translocation and electrolyte disturbances, as evidenced by significantly increased CRP and procalcitonin levels, decreased lymphocyte count and serum sodium levels. In addition, although the incidence of AKI and acute liver injury was similar between the COVID-19 patients with or without GI symptoms, the AST level and creatinine above 133 μmol/L in the COVID-19 patients with GI symptoms were higher than those without GI symptoms. These results highlighted the need to closely monitor liver and kidney functions during the course of the disease.
The functional host cell “receptor” for SARS-CoV-2 is angiotensin converting enzyme 2 (ACE2) (37, 38). The spike glycoprotein (S protein) on the virion surface mediates receptor recognition and membrane fusion, thus exploiting ACE2 for host infection (39). ACE2 receptors are not only distributed in bronchial transient secretory cells (40) but also in various tissues and organs, such as kidneys, small intestine, (41) and testis (42). In the intestines, ACE2 is primarily distributed on the luminal surface of differentiated small intestinal epithelial cells, and is identified as a key regulator of dietary amino acid homeostasis, innate immunity, gut microbial ecology, and transmissible susceptibility to colitis (43). These may mediate the invasion of the virus, activation and amplification of gastrointestinal inflammation (44) and lead to GI symptoms in patients with COVID-19.
The gastrointestinal tract represents a large microbial ecosystem, housing several trillion microbiota. Under normal circumstances, the intestinal microbiota plays a critical role in the maturation of the host immune response (45), influences the regulation of intestinal endocrine functions (46) and maintains the homeostasis of gastrointestinal tract. An increase in gut permeability, bacterial translocation and local responses can be found in patients with critical illness of various causes (47). For example, in intestinal ischemia-reperfusion injury, it has been demonstrated that the reperfused gut can become a source of pro-inflammatory mediators (48) which can be delivered to remote organs and amplify the early systemic inflammatory response (22). Consistent with the results of previous animal studies (22), the presence of GI symptoms is associated with a higher rate of ARDS, non-invasive mechanical ventilation and tracheal intubation in patients with COVID-19. However, our study showed that GI symptoms did not appear to affect the mortality rate among COVID-19 patients but the sample size under power to detect any statistical significances of mortality can not be excluded. Furthermore, at the point of data analysis, some patients were still in the hospital and their long term outcomes are unknown whilst the retrospective nature and a single-center data of our study would call more studies into this during the disease pandemic.
In conclusion, this work is one of the largest cohort of COVID-19 patients with GI symptoms. COVID-19 patients with GI symptoms, as compared with absence of GI symptoms, were associated with high risks of ARDS, non-invasive mechanical ventilation, and tracheal intubation. Therefore, we should pay greater attention to COVID-19 patients with GI and other non-classical symptoms for better care of our patients and remain vigilant in the protection of healthcare providers.
Data Availability Statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics Statement
The studies involving human participants were reviewed and approved by Institutional Review Board at Renmin hospital of Wuhan University (No. WDRY2020-K111, March 12, 2020). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.
Author Contributions
LG, Q-tM, and DM designing research studies, reviewed, and edited the manuscript. YL and J-xL acquiring data. RC, Y-lY, and WL analyzing data and writing the paper. Illustrations and proofreading were performed by YL, FC, and QZ. All authors read and approved the manuscript.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Footnotes
Funding. This work was supported by the National Natural Science Foundation of China (NSFC): 81671948.
References
- 1.World Health Organization Coronavirus Disease 2019 (COVID-19) Situation Report-−184. (2020). Available online at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200722-covid-19-sitrep-184.pdf?sfvrsn=7680210a_2 (accessed July 23, 2020).
- 2.Ma C, Zhang H. COVID-19, a far cry from the influenza. Precis Clin Med. (2020) 3:100–3. 10.1093/pcmedi/pbaa015 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. (2020) 395:507–13. 10.1016/S0140-6736(20)30211-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Wang Y, Liu Y, Liu L, Wang X, Luo N, Ling L. Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen, China. J Infect Dis. (2020) 221:1770–4. 10.1093/infdis/jiaa119 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. (2020) 382:1708–20. 10.1101/2020.02.06.20020974 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. (2020) 323:1061–9. 10.1001/jama.2020.1585 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Wang X, Liu Z, Li J, Zhang J, Tian S, Lu S, et al. Impacts of type 2 diabetes on disease severity, therapeutic effect, and mortality of patients with COVID-19. J Clin Endocrinol Metab. (2020) 105:dgaa535. 10.1210/clinem/dgaa535 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Zhang J, Lu S, Wang X, Jia X, Li J, Lei H, et al. Do underlying cardiovascular diseases have any impact on hospitalised patients with COVID-19? Heart. (2020) 106:1148–53. 10.1136/heartjnl-2020-316909 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. Am J Respir Crit Care Med. (2020) 201:1372–9. 10.1164/rccm.202003-0543OC [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect. (2020) 26:767–72. 10.1016/j.cmi.2020.04.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Ma C, Cong Y, Zhang H. COVID-19 and the digestive system. Am J Gastroenterol. (2020) 115:1003–6. 10.14309/ajg.0000000000000691 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. (2020) 115:766–73. 10.14309/ajg.0000000000000620 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Zhou Z, Zhao N, Shu Y, Han S, Chen B, Shu X. Effect of gastrointestinal symptoms on patients infected with coronavirus disease 2019. Gastroenterology. (2020) 158:2294–7. 10.1053/j.gastro.2020.03.020 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. (2020) 181:894–904.e9. 10.1016/j.cell.2020.03.045 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. (2020) 181:271–80.e8. 10.1016/j.cell.2020.02.052 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. (2020) 581:215–20. 10.1038/s41586-020-2180-5 [DOI] [PubMed] [Google Scholar]
- 17.Du M, Cai G, Chen F, Christiani DC, Zhang Z, Wang M. Multiomics evaluation of gastrointestinal and other clinical characteristics of severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019. Gastroenterology. (2020) 158:2298–2301. 10.1053/j.gastro.2020.03.045 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Zang R, Gomez Castro MF, McCune BT, Zeng Q, Rothlauf PW, Sonnek NM, et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol. (2020) 5:eabc3582. 10.1126/sciimmunol.abc3582 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Cheung KS, Hung IF, Chan PP, Lung KC, Tso E, Liu R, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis. Gastroenterology. (2020) 159:81–95. 10.1053/j.gastro.2020.03.065 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Hu B, Sun R, Wu A, Ni Y, Liu J, Guo F, et al. Severity of acute gastrointestinal injury grade is a predictor of all-cause mortality in critically ill patients: a multicenter, prospective, observational study. Crit Care. (2017) 21:188. 10.1186/s13054-017-1780-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Riwes M, Reddy P. Microbial metabolites and graft versus host disease. Am J Transplant. (2018) 18:23–9. 10.1111/ajt.14443 [DOI] [PubMed] [Google Scholar]
- 22.Meng Q-T, Cao C, Wu Y, Liu H-M, Li W, Sun Q, et al. Ischemic post-conditioning attenuates acute lung injury induced by intestinal ischemia-reperfusion in mice: role of Nrf2. Lab Invest. (2016) 96:1087–104. 10.1038/labinvest.2016.87 [DOI] [PubMed] [Google Scholar]
- 23.National Health Commission of the People's Republic of China . Chinese Management Guideline for COVID-19 (Version 7.0). (2020). Available online at: http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350a8ce964.pdf (accessed May 28, 2020).
- 24.National Health Commission of the People's Republic of China Chinese Management Guideline for COVID-19 (Version 6.0). (2020). Available online at: http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf (accessed May 28, 2020).
- 25.National Health Commission of the People's Republic of China Chinese Management Guideline for COVID-19 (Version 5.0). (2020). Available online at: http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a/files/ab6bec7f93e64e7f998d802991203cd6.pdf (accessed May 28, 2020).
- 26.Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. (2020) 130:2620–9. 10.1172/JCI137244 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.ARDS Definition Task Force. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. (2012) 307:2526–33. 10.1001/jama.2012.5669 [DOI] [PubMed] [Google Scholar]
- 28.Palevsky PM, Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis. (2013) 61:649–72. 10.1053/j.ajkd.2013.02.349 [DOI] [PubMed] [Google Scholar]
- 29.Jin X, Lian J-S, Hu J-H, Gao J, Zheng L, Zhang Y-M, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. (2020) 69:1002–9. 10.1136/gutjnl-2020-320926 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Hajifathalian K, Krisko T, Mehta A, Kumar S, Schwartz R, Fortune B, et al. Gastrointestinal and hepatic manifestations of 2019 novel coronavirus disease in a large cohort of infected patients from New York: clinical implications. Gastroenterology. (2020) 159:1137–40.e2. 10.1053/j.gastro.2020.05.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Borobia AM, Carcas AJ, Arnalich F, Álvarez-Sala R, Monserrat-Villatoro J, Quintana M, et al. A cohort of patients with COVID-19 in a major teaching hospital in Europe. J Clin Med. (2020) 9:1733. 10.3390/jcm9061733 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Mao R, Qiu Y, He J-S, Tan J-Y, Li X-H, Liang J, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. (2020) 5:667–78. 10.1016/S2468-1253(20)30126-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut. (2020) 69:997–1001. 10.1136/gutjnl-2020-321013 [DOI] [PubMed] [Google Scholar]
- 34.Chen A, Agarwal A, Ravindran N, To C, Zhang T, Thuluvath PJ. Are gastrointestinal symptoms specific for COVID-19 infection? A prospective case-control study from the United States. Gastroenterology. (2020) 159:1161–3. 10.1053/j.gastro.2020.05.036 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Han C, Duan C, Zhang S, Spiegel B, Shi H, Wang W, et al. Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes. Am J Gastroenterol. (2020) 115:916–23. 10.14309/ajg.0000000000000664 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. (2020) 382:1708–20. 10.1056/NEJMoa2002032 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. (2003) 426:450–4. 10.1038/nature02145 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. (2020) 367:1444–8. 10.1126/science.abb2762 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. (2020) 579:270–3. 10.1038/s41586-020-2012-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Lukassen S, Chua RL, Trefzer T, Kahn NC, Schneider MA, Muley T, et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. (2020) 39:e105114. 10.15252/embj.2020105114 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal–oral transmission. Gastroenterology. (2020) 158:1518–9. 10.1053/j.gastro.2020.02.054 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Wang Z, Xu X. scRNA-seq profiling of human testes reveals the presence of the ACE2 receptor, a target for SARS-CoV-2 infection in Spermatogonia, Leydig and Sertoli Cells. Cells. (2020) 9:920. 10.20944/preprints202002.0299.v1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Hashimoto T, Perlot T, Rehman A, Trichereau J, Ishiguro H, Paolino M, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. (2012) 487:477–81. 10.1038/nature11228 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Zhang H, Li H-B, Lyu J-R, Lei X-M, Li W, Wu G, et al. Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection. Int J Infect Dis. (2020) 96:19–24. 10.1016/j.ijid.2020.04.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Fulde M, Hornef MW. Maturation of the enteric mucosal innate immune system during the postnatal period. Immunol Rev. (2014) 260:21–34. 10.1111/imr.12190 [DOI] [PubMed] [Google Scholar]
- 46.Neuman H, Debelius JW, Knight R, Koren O. Microbial endocrinology: the interplay between the microbiota and the endocrine system. FEMS Microbiol Rev. (2015) 39:509–21. 10.1093/femsre/fuu010 [DOI] [PubMed] [Google Scholar]
- 47.Wiest R, Rath HC. Gastrointestinal disorders of the critically ill. Bacterial translocation in the gut. Best Pract Res Clin Gastroenterol. (2003) 17:397–425. 10.1016/S1521-6918(03)00024-6 [DOI] [PubMed] [Google Scholar]
- 48.Meng Q-T, Chen R, Chen C, Su K, Li W, Tang L-H, et al. Transcription factors Nrf2 and NF-κB contribute to inflammation and apoptosis induced by intestinal ischemia-reperfusion in mice. Int J Mol Med. (2017) 40:1731–40. 10.3892/ijmm.2017.3170 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.